This is a 4 year, Phase 2b, randomized, placebo-controlled, double-blind study enrolling approximately 498 participants worldwide. This study involves an investigational medication which is a liposomal active immunotherapy targeting tau protein. The study will involve up to 23 study visits and 5 phone calls.
Eligible participants will be randomly assigned to one of two groups, one which receives the investigational medication and one that receives placebo. A placebo is an inactive substance that is designed to look like a medication. The investigational medication or the placebo will be administered by injection in the upper arm.
What is the purpose of the Janssen ReTain Trial?
The purpose of the Janssen ReTain trial is to assess the effect of the investigational medication on cognitive decline. In addition, the effects of the investigational medication on the accumulation of tau, as measured by tau PET scan, will be evaluated.
Eligibility
The participants in this study must be between the ages of 55-75 and are cognitively normal. All participants must have a study partner, who has at least weekly contact with them, who can accompany them to some study visits.
Interested participants can contact the Memory and Aging Program Outreach Team at (401) 455-6402 or by sending an email to memory@butler.org to discuss additional eligibility criteria.
Contact Form
To learn more about the study or to enroll, please contact our research team by filling out the form below.
